Sibeprenlimab clinically reduces proteinuria in adults with immunoglobulin A nephropathy (IgAN), according to data from a prespecified analysis of the phase 3 VISIONARY trial. The findings were ...

In patients with immunoglobulin A nephropathy (IgAN), higher levels of proteinuria and lower baseline estimated glomerular filtration rate (eGFR) are strongly associated with adverse kidney outcomes — ...